Philogen S.p.A. (BIT:PHIL)
Italy
· Delayed Price · Currency is EUR | Market Cap | 837.85M |
| Revenue (ttm) | 319.73M |
| Net Income (ttm) | 229.68M |
| Shares Out | 40.28M |
| EPS (ttm) | 5.70 |
| PE Ratio | 3.65 |
| Forward PE | n/a |
| Dividend | 0.70 (3.37%) |
| Ex-Dividend Date | n/a |
| Volume | 11,190 |
| Average Volume | 26,959 |
| Open | 20.55 |
| Previous Close | 20.80 |
| Day's Range | 20.55 - 21.10 |
| 52-Week Range | 19.56 - 27.80 |
| Beta | 0.01 |
| RSI | 43.66 |
| Earnings Date | May 12, 2026 |
About Philogen
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]
Financial Performance
In 2025, Philogen's revenue was 319.73 million, an increase of 313.81% compared to the previous year's 77.26 million. Earnings were 229.68 million, an increase of 407.10%.
Financial StatementsNews
Philogen Earnings Call Transcript: H2 2025
Reported EUR 230 million net profit and EUR 380 million cash for 2025, with a EUR 0.70 dividend per share. Advanced key oncology programs, including Nidlegy and Fibromun, and secured major licensing deals. Regulatory submissions and pivotal trials are on track.
Philogen Earnings Call Transcript: H1 2025
A transformative licensing deal with Racebio has significantly strengthened liquidity, enabling expanded investment in late-stage clinical programs and infrastructure. Key trials in oncology and dermatology are progressing, with major data readouts and regulatory milestones expected in 2025–2026.
Philogen Earnings Call Transcript: H2 2024
2024 saw revenues triple to €77.5M, driven by contract income, with EBITDA over €40M and net profit of €45M. Major clinical progress was made in oncology programs, with pivotal trial readouts expected in 2025 and a strong cash position of €113.7M.
Philogen Earnings Call Transcript: Q3 2024
Major clinical milestones achieved in skin, brain, and soft tissue cancers, with pivotal trials completed or nearing completion and regulatory filings advancing in both Europe and the US. Small molecule pipeline shows strong potential to outperform current market leaders in prostate cancer.
Philogen Earnings Call Transcript: H1 2024
Announced a global commercialization deal with Sun Pharma for Nidlegy and Fibromun, with strong clinical progress in melanoma, non-melanoma skin cancers, and soft tissue sarcoma. Financials show increased expenses and a net loss, but liquidity remains strong and positive year-end results are expected.
Philogen Transcript: Status Update
Targeted cancer therapies show strong clinical progress, with Nidlegy doubling recurrence-free survival in melanoma and high response rates in BCC and SCC. Regulatory filings are advancing, new trials are launching, and commercial partnerships are being pursued for global market access.